Analyst Ratings for Biogen (BIIB) [Buys]
BIIB Rating Summary
BIIB Price Target Summary
- Highest: $398.00 (Goldman Sachs)
- Lowest: $230.00 (Barclays)
- Average: $299.88
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$299.88 (+39.1%)
* Over Last 12-Mos
Rating Score: 6.9 / 10 Percentile Rank: 75%
Rating Score: 6.9 / 10 Percentile Rank: 75%
Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
---|---|---|---|---|---|---|---|---|
12/20/2023 | Cantor Fitzgerald | Eric Schmidt | New Coverage | Overweight (N/A) |
N/A (N/A) |
251.69 (215.63) |
-14.33% | Details |
12/7/2023 | Raymond James | Danielle Brill | Upgrade | Outperform (Market Perform) |
283.00 (N/A) |
233.87 (215.63) |
-7.8% | Details |